Your browser has either disabled or does not support javascript. Javascript is required for full website experience.
BiondVax Pharmaceuticals Ltd. ADR
BVXV
$
4
17%
Wed February 10th, 2021
21:30
Press Releases
BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering
PR Newswire
Tue February 2nd, 2021
21:30
Press Releases
BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering
PR Newswire
Thu January 28th, 2021
23:48
Press Releases
BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares
PR Newswire
20:23
Press Releases
BiondVax Announces Third Quarter 2020 Financial Results & Business Update
PR Newswire
Fri October 23rd, 2020
21:03
Analysis
Why BiondVax Pharmaceuticals Stock Imploded Today
The Motley Fool
Fri October 2nd, 2020
10:00
Press Releases
BiondVax Announces At-The-Market (ATM) Equity Offering Program
PR Newswire
Tue September 1st, 2020
22:21
Analysis
BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company
Seeking Alpha
Thu August 20th, 2020
20:01
Press Releases
BiondVax Announces Second Quarter 2020 Financial Results
PR Newswire
Tue June 30th, 2020
20:01
Press Releases
BiondVax Announces First Quarter 2020 Financial Results
PR Newswire
Fri June 12th, 2020
12:00
Press Releases
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
PR Newswire